Our findings showed that the use of etoposide combined with AraC plus G-CSF regimen could increase the adequate and optimal collection rates in patients with MM (100% vs. 94.5%) by 1.2 and 1.1 apheresis procedures (mean), respectively. This evidence concerns the gene CSF3 and Miyoshi myopathy.